EGFR and non-small cell lung carcinoma: A recent clinical trial (NCT02151981) showed that AZD9291 significantly improved objective response rate (ORR) and PFS in T790 M-mutant NSCLC patients who had disease progression on first-line EGFR-TKIs [93].